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Summary. The expression of apoptosis-related genes BCL2,
BAX, BCL2L1, BCL2A1, MCL1, DAPK1 and MYC was
studied by quantitative real-time polymerase chain reaction
on total RNA samples from patients with acute lympho-
blastic leukaemia (ALL, n ¼ 16), acute myeloid leukaemia
(AML, n ¼ 27), chronic myeloid leukaemia (CML, n ¼ 12),
mantle cell lymphoma (MCL, n ¼ 19) and chronic lymphoid
leukaemia (CLL, n ¼ 32). BCL2, BAX, BCL2A1, MCL1,
DAPK1 and MYC were overexpressed in all patient groups.
BCL2L1 was underexpressed in CLL and CML, but not in
AML, ALL and MCL. MCL1 levels were significantly higher
in CD13 and CD33-positive ALL, and in CD56-positive AML
samples. BCL2, BCL2L1, BCL2A1 and MCL1 were overex-
pressed and DAPK1 was underexpressed in CLL samples
with a 11q23 deletion. MYC overexpression was signifi-
cantly associated with shorter overall survival in MCL
(P < 0Æ01). AML patients with a normal karyotype showed
a higher frequency of BCL2A1 overexpression (P < 0Æ001)
than those with an abnormal karyotype.
Keywords: apoptotic genes, gene expression, hae-
matological malignancies, quantitative real-time PCR,
prognosis.
Apoptosis plays a critical role in the normal development of
tissue homeostasis as well as in defence against infections.
Deregulation of apoptosis has been shown to contribute to
the development of cancer, autoimmune diseases and
degenerative disorders (Reed, 1998, 1999, 2000). A
number of genes are involved in the regulation of apoptosis,
among them the family of BCL2 genes. They regulate
cellular responsiveness to a wide variety of death-inducing
stimuli, including growth factor deprivation, the presence of
glucocorticoids, receptor antibodies, and radio- or chemo-
therapeutical agents (Reed, 1998, 1999, 2000). Some of
the BCL2 family members are antiapoptotic, such as BCL2,
MCL1, BCL2A1 and BCL2L1, and others are pro-apoptotic
such as BAX, BAK, BAD and BCLXS (Oltvai et al, 1993;
Chao & Korsmeyer, 1998; Srivastava et al, 1999). The pro-
and antiapoptotic proteins can form heterodimers and the
ratio of these determines the execution of apoptosis (Oltvai
et al, 1993; Adams & Cory, 1998; Schimmer et al, 2001).
Another important regulator in apoptosis is the MYC
oncogene. It has maintained a highly conserved sequence
through evolution and encodes a transcription factor that
plays an important role in a number of biological functions,
including cell proliferation, differentiation and apoptosis
(Cole, 1986).
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Aberration of apoptosis has been observed in haemato-
logical neoplasms. Chromosomal translocations affecting
apoptosis regulator genes, such as t(14;18) of the BCL2
gene, are well defined in haematological malignancies
(Tsujimoto et al, 1985). The bcl2 protein inhibits apoptosis
by forming dimers with bax and bak (Schimmer et al, 2001).
It regulates cell death by controlling mitochondrial mem-
brane permeability via inhibition of caspase activity and
prevents the release of cytochrome c (Jacobson et al, 1993;
Shimizu et al, 1999). BAX, which is a pro-apoptotic gene,
induces the release of cytochrome c. Furthermore, the ratio of
bcl2 to bax determines cell survival or death after an
apoptotic stimulus (Oltvai et al, 1993). BCL2L1 is a highly
conserved gene encoding an alternative splicing of two
isoforms with antagonistic functions, the shorter with a pro-
apoptotic and the longer with an antiapoptotic function
(Boise et al, 1993). Bcl2L1 forms dimers with bax and bak
and has been shown to be an independent regulator of
programmed cell death by preventing apoptosis (Boise et al,
1993; Korsmeyer, 1999). BCL2A1 prevents apoptosis
induced by the p53 tumour suppressor protein (D’Sa-Eipper
et al, 1996). MCL1 participates in myeloid cell differenti-
ation and has sequence homology with BCL2 (Kozopas et al,
1993; Bae et al, 2000). Death-associated protein kinase
(DAPK1) is a potential mediator of c-interferon-induced cell
death: when deregulated, it behaves as an oncogene or
growth suppressor (Deiss et al, 1995)1 . Overexpression of
MYC has been found in numerous human tumours,
including several haematological disorders with T- and
B-cell lineage involvement (Marcu et al, 1992; Sakamuro &
Prendergast, 1999).
Our recent studies of acute myeloid leukaemia (AML)
and chronic lymphocytic leukaemia (CLL) using the
microarray technology revealed altered expression of
several apoptosis-related genes (Aalto et al, 2001; Larr-
amendy et al, 2002).
In this study we determined the expression levels of seven
genes (BCL2, BAX, BCL2L1, BCL2A1, MCL1, DAPK1, MYC)
using quantitative real-time reverse transcription poly-
merase chain reaction (QRT-PCR). We set out to identify
diagnostic and prognostic markers for acute lymphoid
leukaemia (ALL), acute myeloid leukaemia (AML), chronic
myeloid leukaemia (CML), mantle cell lymphoma (MCL) and
chronic lymphocytic leukaemia (CLL).
PATIENTS AND METHODS
ALL, AML and CML samples
Bone marrow samples were obtained from 16 ALL patients,
27 AML patients and 12 CML patients at the Helsinki
University Central Hospital, Helsinki, Finland. Table I shows
the key data of these patients. Bone marrow aspirates were
diluted 1:10 in RNA/DNA stabilization reagent for blood/
bone marrow (Boehringer Mannheim GmbH, Mannheim,
Germany) containing guanidinium thiocyanate and in
TritonÒ X-100 (Boehringer) for simultaneous cell lysis and
stabilization of nucleic acids according to the supplier’s
instructions. Lysates were stored at )70°C until RNA
extraction.
Mantle cell lymphoma (MCL)
Samples were obtained from 19 patients diagnosed at the
Helsinki University Central Hospital (Table I). All patients
were CD5+, CD19+, CD20+, CD23– and cyclin D1+. The
International Prognostic Index (IPI) was used for risk
grouping of the patients (Blay et al, 1998).
CLL
Peripheral blood specimens were obtained from 32 patients
referred to the CLL out-patient clinic at Tampere University
Central Hospital (Tampere, Finland) (Table I). All had a
blood lymphocyte count of 30 · 109/l or higher. These
patients were diagnosed and staged according to standard
clinical, morphological and immunophenotypic criteria and
the Binet system. All patients had a CD19+/CD5+/CD23+
immunophenotype. The proportions of monocytes and
polyclonal T and B lymphocytes were 1–13%, indicating
that 87–99% of the isolated cells represented the leukaemic
population.
Control samples
Bone marrows from four healthy individuals were used as
controls for the ALL, AML and CML samples. References for
MCL and CLL samples were CD19+ B cells, which were
purified from the adenoid palatine tonsils of six healthy
children and pooled. B cells were purified using microbeads
conjugated to a monoclonal CD19 antibody (Miltenyi
Biotec, Bergisch Gladbach, Germany). The proportion of T
lymphocytes was less than 5%, indicating that 95% of the
isolated cells represented B-lymphocyte population.
RNA isolation
AML, ALL, CML and control samples. Total nucleic acid
was isolated from samples using the mRNA isolation kit for
blood/bone marrow (Boehringer) based on magnetic glass
particle technology following the manufacturer’s instruc-
tions.
CLL. Lymphocytes were isolated from patient blood using
one-step density gradient centrifugation in Ficoll–Paque
(Pharmacia Fine Chemicals, Uppsala, Sweden), and total
RNA was extracted using the Trizol Reagent (Gibco BRL,
Grand Island, NY, USA).
MCL. Total RNA was isolated from deep-frozen tissue
specimens using an RNeasy Mini Kit (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions.
DNase I treatment
All RNA samples were treated with DNase I (Boehringer) to
remove genomic DNA contamination from the preparations
according to the manufacturer’s instructions. RNA quality
and integrity were checked by electrophoresis using 1%
agarose gel with ethidium bromide staining and UV trans-
illumination. RNA concentrations were measured using a
spectrophotometer at a wavelength of 260 nm.
QRT-PCR
QRT-PCR was performed on all samples to determine
the expression of seven apoptosis-related genes (BCL2,
BAX, BCL2L1, BCL2A1, MCL1, DAPK1, MYC) and one
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housekeeping gene for b-actin (ACTB) (Table II). Comple-
mentary DNA (cDNA) was synthesized using 0Æ5 lg of
DNase-I-treated total RNA and a First Strand cDNA
Synthesis kit for RT-PCR (Roche Diagnostics, Indianapolis,
IN, USA). Gene-specific primers were designed and synthes-
ized by TIB MOLBIOL (Berlin, Germany). PCR was per-
formed in a LightCycler thermal cycler (Roche). Each PCR
reaction consisted of 1 ll of DNA Master SYBR Green I mix
(LightCycler-FastStart DNA Master SYBR Green I kit,
Roche; containing Taq polymerase, dNTP, MgCl2, and SYBR
Green I dye), 1 ll of cDNA and 2Æ5–5Æ0 pmol of primers.
The amplification programme included an initial denatur-
ation at 95°C for 8 min, 45–55 cycles with denaturation at
95°C for 10 s, annealing at 58–62°C for 5 s and extension
at 72°C for 20 s. Amplifications were followed by melting
curve analysis using one cycle at 95°C for 0 s, 65°C for
10 s, and 95°C for 0 s at the acquisition step mode. A
negative control without a cDNA template was run simul-
taneously with every assay. For each cDNA sample the PCR
was run in duplicate. Standard curves were obtained using
serial dilutions of the beta-globulin gene (DNA Control kit;
Roche) according to the supplier’s instructions. The con-
centration of each gene product was determined on the
basis of a kinetic approach using the lightcycler software
(Roche). The levels of ACTB were used for normalization of
RNA quantity and quality differences in all samples.
Statistical analysis of data
Statistical analysis was performed using the Statistical
Package for Social Sciences (spss) for Windows (Version
9Æ0), with the Student’s t-test and Levene’s test for the gene
expression comparisons. The overall survival related to gene
expression was analysed by the Kaplan–Meier method.
RESULTS
The expression levels of BCL2, BAX, BCL2L1, BCL2A1,
MCL1, DAPK1 and MYC were determined by QRT-PCR
(Table III). Figure 1A and B shows the ratios of expression
levels in each sample. ALL, AML and CML samples were
compared with RNA isolated from the bone marrow of
healthy donors, whereas MCL and CLL samples were
compared with RNA isolated from tonsillar B cells.
BCL2 and BAX were overexpressed in all patients
(Table III). The BCL2/BAX ratio was highest in CLL
(1Æ844), followed by ALL (0Æ895), MCL (0Æ44), AML
(0Æ067) and CML (0Æ036). The BCL2L1 gene was underex-
pressed in CLL and CML, but the levels were higher than
those of controls in AML, ALL and MCL. BCL2A1, MCL1,
DAPK1 and MYC were overexpressed in all patient groups
(Table III).
Risk groups and the gene expression
We observed statistically significant differences in the
expression of MCL1 between high risk (HR) (53Æ35 ±
38Æ82 ng/ll, P < 0Æ05), intermediate risk (IR) (9Æ93 ±
4Æ32 ng/ll) and standard risk (SR) 10Æ43 ± 2Æ58 ng/ll
groups of ALL. Gene expression levels in the MCL
subgroups (IPI), and in the CLL subgroups (Binet) did notT
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differ. With the exception of French-American-British (FAB)
types AML M2 and M4, other subtype groups were too small
to enable statistical analyses. Subtypes M2 and M4 did not
show statistically significant alterations in gene expression.
Immunophenotypes and gene expression
There was a statistically significant difference in the expres-
sion of BCL2L1 and MCL1 in the CD13+/CD33+ and
negative ALL samples (BCL2L1: 0Æ2812 ± 0Æ6482 ng/ll
and 0Æ048 ± 0Æ0328 ng/ll, P ¼ 0Æ049; MCL1: 35Æ9220 ±
38Æ9558 ng/ll and 16Æ7599 ± 19Æ1491 ng/ll; P ¼ 0Æ026).
The CD56-positive and -negative AML patients showed
a statistically significant difference in the level of
MCL1 (54Æ22 ± 74Æ94 ng/ll and 35Æ43 ± 22Æ96 ng/ll;
P ¼ 0Æ027).
Cytogenetic alterations and gene expression
We observed that CLL patients with the 11q23 deletion
showed significantly higher expression of BCL2 than
patients without the deletion (11q23+: 3Æ38 ± 4Æ62 ng/ll
versus 11q23–: 20Æ74 ± 21Æ63 ng/ll; P ¼ 0Æ0001), BCL2L1
(11q23+: 0Æ0002 ± 0Æ0004 ng/ll versus 11q23–: 0Æ0009 ±
0Æ0018 ng/ll; P ¼ 0Æ001), BCL2A1 (11q23+: 3Æ75 ±
3Æ63 ng/ll versus 11q23–: 15Æ40 ± 13Æ15 ng/ll; P ¼
0Æ0001) and MCL1 (11q23+: 43Æ01 ± 88Æ53 ng/ll versus
11q23–: 291Æ15 ± 344Æ74 ng/ll; P ¼ 0Æ001), and lower
expression of DAPK1 (11q23+: 0Æ0342 ± 0Æ0037 ng/ll ver-
sus 11q23–: 0Æ0289 ± 0Æ0170 ng/ll; P < 0Æ05). In AML, the
expression of BCL2A1 was different between samples with
normal (n ¼ 13) and abnormal karyotypes (n ¼ 14)
(16Æ0407 ± 21Æ0988 ng/ll versus 4Æ6976 ± 7Æ6931
ng/ll, P ¼ 0Æ001).
Survival and gene expression
We compared the expression of genes with the overall
survival in MCL. There was significant negative association
between the level of MYC and the overall survival
(P ¼ 0Æ01) (Fig 2), but not with the IPI (P ¼ 0Æ36), age
(P ¼ 0Æ27) or gender (P ¼ 0Æ39). The patients alive at the
end of the study had significantly lower levels of MYC than
those who had died (109Æ05 ± 101Æ28 ng/ll, 286Æ48 ±
252Æ78 ng/ll; P < 0Æ05).
The overall survival was lower in patients with the blastoid
form of MCL (blastoid variant 17Æ37 ± 17Æ04 months and
normal variant 32Æ19 ± 24Æ9 months) and the expres-
sion of BCL2L1 was significantly higher in blastoid sub-
types (0Æ0341 ± 0Æ0361 ng/ll and 0Æ0085 ± 0Æ0361 ng/ll,
P ¼ 0Æ03).
DISCUSSION
In the present study, we analysed the expression of BCL2,
BAX, BCL2L1, BCL2A1, MCL1, DAPK1 and MYC in
different types of haematological malignancies by QRT-
PCR using the SYBR Green I method for the quantification
of PCR products.
As controls, we used bone marrow samples from healthy
donors for the ALL, AML and CML bone marrow samples.
CD19+ B cells were pooled from six normal adenoids andT
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used as reference for the CLL and MCL samples. Neither
control is a perfect means to verify whether or not gene
expression differences in the cancer samples are attributable
merely to the disease per se and not to the maturation stage
or lineage involvement of haematopoietic cells. Neverthe-
less, although the stem cell from which the malignancy
originates is unidentified, the selection of controls is a
disputable issue. Therefore, the results must be interpreted
with caution. For example, CD19+ B cells from children,
which we used as controls for CLL and MCL, are likely to be
active, and therefore less apoptotic, than CD19+ lymph
nodes from adults or peripheral blood B cells. It should,
however, be noted that the control we used was the same
for all patients of each disease group. Thus the selection of
controls did not have an effect on gene expression
differences within the same disease, and any associations
between gene expression and clinical parameters can be
interpreted reliably.
Fig 2. Overall survival of mantle cell lymphoma patients in relation
to the detected MYC concentrations. Patients expressing MYC <
mean MYC concentration (- - - - ): overall survival 43Æ13 months;
median 49Æ36 months. Patients expressing MYC > mean MYC
concentration (——): overall survival 14Æ30 months; median
11Æ57 months. Overall survival versus MYC P ¼ 0Æ01.
Fig 1. (A) The expression profile of seven apoptosis-related genes
in acute lymphoblastic (ALL) (n ¼ 16), acute myeloid (AML)
(n ¼ 27) and chronic myeloid leukaemia (CML) samples. Meas-
ured gene expressions compared with healthy bone marrow con-
trols. Red represents upregulated genes and green represents
downregulated genes. The samples are presented on the right side
of the image and the studied genes on the top. Grade of colour
correlates to the degree of expression as shown on the scale at
the bottom of the image. The scale is shown from )10 to 10 in
log. (B) The expression profile of seven apoptosis genes in mantle
cell lymphoma (n ¼ 19) and chronic lymphoid leukaemia
(n ¼ 32) samples. Red represents upregulated genes and green
represents downregulated genes. Measured gene expressions were
compared with CD19+ cells from adenoids. The samples are pre-
sented on the right side of the image and the studied genes on the
top. Grade of colour correlates to the degree of expression as
shown on the scale at the bottom of the image. The scale is from
)10 to 10 in log.
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Patient groups and gene expression
BCL2 was overexpressed in all patients. This gene is
involved in both normal lymphoid development and
lymphomas with the t(14;18) translocation (Kozopas et al,
1993). High levels of the bcl2 protein have been reported
even in the absence of t(14;18), for example in CLL together
with a high level of the mcl-1 protein (Gottardi et al, 1996)
and in diffuse large B-cell lymphoma (Monni et al, 1999)2 .
BAX showed the highest overexpression in MCL. Muta-
tions in BAX have been documented in up to 20% of
haematopoietic malignancies (Meijerink et al, 1998). The
bcl2:bax ratio was found to be inversely related with drug-
induced apoptosis in vitro and with clinical response to
chemotherapy (Pepper et al, 1996)3 . In our study, the ratio
was highest in CLL, followed by ALL, MCL, AML and CML.
The functions of BCL2L1 (underexpressed in CML and CLL)
and DAPK1 (overexpressed in MCL) in haematological
malignancies are still largely unknown, although BCL2L1
has been found to be overexpressed in about half of human
cancers associated with resistance to radiotherapy and
chemotherapy (Nicot et al, 2000).
Overexpression of MCL1 (in our CLL and CML patients)
has been indicated to inhibit cell death in human cell lines
less effectively than BCL2 (Krajewski et al, 1995) and to
have an important role in the regulation of B cells (Lomo
et al, 1997).
Our finding of overexpressed MYC and BCL2L1 in MCL is
in concordance with two previous microarray analyses
(Hofmann et al, 2001; Zhu et al, 2002). Furthermore, the
present results and those by Zhu and colleagues give
evidence that the overexpression of these genes is mainly
associated with a blastoid morphology of MCL cells.
BCL2L1 and MCL1 were significantly overexpressed in
CD13+/CD33+ ALL patients. MCL1 levels in CD56+ AML
patients were significantly higher than in CD56– patients.
Recently, it was reported that high expression of MCL1
correlates with resistance to chemotherapeutical agents
(Kaufmann et al, 1998). CD56 positivity is otherwise
associated with a poor prognosis in AML (Di Bona et al,
2002). Whether a cause-and-effect relationship exists
between these two phenomena is still open to question.
An important role for MCL1 in the co-ordination of the
BCL2 gene family in cell phenotype differentiation has
recently been identified (Craig 2002).
BCL2A1 levels in AML were significantly higher in
samples with normal rather than abnormal karyotypes. It
is generally acknowledged that approximately 40% of AML
cases have a normal karyotype. To identify prognostic and
follow-up markers for these patients, characterization of
gene expression alterations is considered to be important.
Our finding that overexpression of BCL2A1 is a character-
istic phenomenon for a subtype of AML patients with a
normal karyotype needs be confirmed with a larger series of
patients (Grimwade et al, 1998).
The antiapoptotic BCL2, BCL2L1, BCL2A1 and MCL1
genes were significantly overexpressed and the pro-apop-
totic DAPK1 was underexpressed in CLL patients with a
11q23 deletion. The loss of 11q23 is one of the most
common structural chromosomal changes in CLL and is
associated with the progression of the disease (Zhu et al,
2000). The alterations in expression levels of anti- and pro-
apoptotic genes we observed support the results of previous
cDNA array studies by Aalto and colleagues who showed
that patients with a 11q23 deletion form a subtype of CLL
(Aalto et al, 2001).
The follow up for all patient groups other than MCL was
too short to apply the Kaplan–Meier survival curve assess-
ment. In this study, the most important novel clinical
finding was the significant association of MYC overexpres-
sion with shorter overall survival in MCL. Many molecular
and clinicopathological variables have been investigated in
this lymphoma type but few prognostical markers have
been found. Other than tumour-related factors, blastoid
morphology has also been shown to be associated with poor
prognosis (Bernard et al, 2001). In the present study six
patients with blastoid morphology showed shorter overall
survival and a higher frequency of MYC overexpression
than patients with typical MCL morphology. However, these
differences were not statistically significant. Recently, MYC
overexpression has been observed in association with
blastoid morphology (Bea et al, 1999; Hernandez et al,
1999; Zhu et al, 2002). However, survival had not been
studied previously. Whether MYC overexpression is an
independent prognostic marker in MCL needs to be studied
in a larger patient group.
To conclude, the aberrant expression of the apoptotic
genes was observed to be associated with immunopheno-
typic and cytogenetic findings and with overall survival in
leukaemias and lymphomas.
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